Cameron JS: Lupus nephritis. J Am Soc Nephrol. 1999, 10: 413-424.
MacGowan JR, Ellis S, Griffiths M, Isenberg DA: Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford). 2002, 41: 981-987. 10.1093/rheumatology/41.9.981.
Martins L, Rocha G, Rodrigues A, Santos J, Vasconcelos C, Correia J, Farinha F, Almeida I, Barbosa P, Guimaraes S: Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol. 2002, 57: 114-119.
Faurschou M, Starklint H, Halberg P, Jacobsen S: Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006, 33: 1563-1569.
Davidson A, Aranow C: Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006, 18: 468-475.
Penkowa M: Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J. 2006, 273: 1857-1870. 10.1111/j.1742-4658.2006.05207.x.
Carrasco J, Penkowa M, Hadberg H, Molinero A, Hidalgo J: Enhanced seizures and hippocampal neurodegeneration following kainic acid-induced seizures in metallothionein-I + II-deficient mice. Eur J Neurosci. 2000, 12: 2311-2322. 10.1046/j.1460-9568.2000.00128.x.
Giralt M, Penkowa M, Hernandez J, Molinero A, Carrasco J, Lago N, Camats J, Campbell IL, Hidalgo J: Metallothionein-1+2 deficiency increases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin 6. Neurobiol Dis. 2002, 9: 319-338. 10.1006/nbdi.2002.0480.
Penkowa M, Florit S, Giralt M, Quintana A, Molinero A, Carrasco J, Hidalgo J: Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res. 2005, 79: 522-534. 10.1002/jnr.20387.
Li X, Chen H, Epstein PN: Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem. 2004, 279: 765-771. 10.1074/jbc.M307907200.
Youn J, Lynes MA: Metallothionein-induced suppression of cytotoxic T lymphocyte function: an important immunoregulatory control. Toxicol Sci. 1999, 52: 199-208. 10.1093/toxsci/52.2.199.
Lynes MA, Borghesi LA, Youn J, Olson EA: Immunomodulatory activities of extracellular metallothionein. I. Metallothionein effects on antibody production. Toxicology. 1993, 85: 161-177. 10.1016/0300-483X(93)90040-Y.
Nartey NO, Banerjee D, Cherian MG: Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of fetal human liver and kidney and its changes during development. Pathology. 1987, 19: 233-238. 10.3109/00313028709066555.
Mididoddi S, McGuirt JP, Sens MA, Todd JH, Sens DA: Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol Lett. 1996, 85: 17-27. 10.1016/0378-4274(96)03632-6.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.
Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, d'Ascanio A, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 527-539.
Churg J, Sobin LH: Renal disease: classification and atlas of glomerular disease. Tokyo: Igaku-Shoin. 1982, 127-131.
Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983, 75: 382-391. 10.1016/0002-9343(83)90338-8.
Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J: Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia. 2000, 32: 271-285. 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5.
Penkowa M, Hidalgo J, Moos T: Increased astrocytic expression of metallothioneins I + II in brainstem of adult rats treated with 6-aminonicotinamide. Brain Res. 1997, 774: 256-259. 10.1016/S0006-8993(97)81716-7.
Gasull T, Rebollo DV, Romero B, Hidalgo J: Development of a competitive double antibody radioimmunoassay for rat metallothionein. J Immunoassay. 1993, 14: 209-225. 10.1080/15321819308019851.
Penkowa M, Moos T, Carrasco J, Hadberg H, Molinero A, Bluethmann H, Hidalgo J: Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia. 1999, 25: 343-357. 10.1002/(SICI)1098-1136(19990215)25:4<343::AID-GLIA4>3.0.CO;2-V.
Penkowa M, Espejo C, Ortega-Aznar A, Hidalgo J, Montalban X, Martinez Caceres EM: Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell Mol Life Sci. 2003, 60: 1258-1266.
Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC: Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol. 1997, 8: 1537-1545.
Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int. 1998, 53: 1608-1615. 10.1046/j.1523-1755.1998.00905.x.
Tang S, Leung JC, Abe K, Chan KW, Chan LY, Chan TM, Lai KN: Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest. 2003, 111: 515-527.
Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH: Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol. 1999, 10: 69-76.
Abbate M, Zoja C, Rottoli D, Corna D, Tomasoni S, Remuzzi G: Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int. 2002, 61: 2066-2077. 10.1046/j.1523-1755.2002.00380.x.
Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G: Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 2007, 56: 1569-1578. 10.1002/art.22524.
Daniel L, Sichez H, Giorgi R, Dussol B, Figarella-Branger D, Pellissier JF, Berland Y: Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int. 2001, 60: 2215-2221. 10.1046/j.1523-1755.2001.00055.x.
Illei GG, Lipsky PE: Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep. 2004, 6: 382-390. 10.1007/s11926-004-0013-4.
Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C: Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol. 2007, 179: 7166-7175.
Derksen RH, Hene RJ, Kater L: The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single center. Lupus. 1992, 1: 97-103. 10.1177/096120339200100207.
Ravinal RC, Costa RS, Coimbra TM, Pastorello MT, Coelho EB, Dantas M, dos RM: Classes, activity and chronicity indices, and alpha-smooth muscle actin expression as prognostic parameters in lupus nephritis outcome. Lupus. 2002, 11: 82-87. 10.1191/0961203302lu153oa.
Austin HA, Boumpas DT, Vaughan EM, Balow JE: High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995, 10: 1620-1628.
Austin HA, Boumpas DT, Vaughan EM, Balow JE: Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994, 45: 544-550. 10.1038/ki.1994.70.
Conlon PJ, Fischer CA, Levesque MC, Smith SR, St Clair EW, Allen NB, Fleming JA, Howell DN: Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol. 1996, 46: 170-175.
Klaassen CD, Liu J, Choudhuri S: Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol. 1999, 39: 267-294. 10.1146/annurev.pharmtox.39.1.267.
Ogra Y, Suzuki KT: Nuclear trafficking of metallothionein: possible mechanisms and current knowledge. Cell Mol Biol (Noisy-le-grand). 2000, 46: 357-365.
Chung RS, West AK: A role for extracellular metallothioneins in CNS injury and repair. Neuroscience. 2004, 123: 595-599. 10.1016/j.neuroscience.2003.10.019.